Article
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
Advances in therapy - 1 Jun 2017
Sato Ken, Chayama Kazuaki, Alves Katia, Toyoda Hidenori, Suzuki Fumitaka, Kato Koji, Rodrigues Lino, Zhang Xinyan, Setze Carolyn, Pilot-Matias Tami, Burroughs Margaret, Redman Rebecca, Kumada Hiromitsu
Abstract excerpt
INTRODUCTION: In Japan, hepatitis C virus (HCV) genotype (GT) 2 accounts for approximately 32% of HCV infections. Limited treatment options exist in Japan for HCV GT2-infected patients. GIFT-II was a phase 3, randomized, open-label study evaluating the efficacy and safety of 16- and 12-week regimens of co-formulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus ribavirin (RBV) in Japanese adults with HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.